Metraipolis › archive › dc_e28859c66ccd
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42036408
- DOI
- 10.1038/s41413-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T04:49:56.146Z
- SHA-256 of the archived text
7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127- Stable URL of this page
https://metraipolis.com/documento/dc_e28859c66ccd
How to cite
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408 — Europe PMC (en), https://europepmc.org/article/MED/42036408 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e28859c66ccd (Metraipolis archive dc_e28859c66ccd, sha256 7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127)
BibTeX
@misc{dce28859c66ccd,
title = {A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42036408},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e28859c66ccd; sha256 7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42036408. Agents can read the archived copy with the MCP tool read_document.